Announced details
Third-line treatment for adenocarcinoma of the stomach and esophagus
Clear tumor shrinkage was observed in 3 of 16 patients, 2 of whom survived for more than 5 years. In 1 patient, the primary gastric and esophageal tumors and lymph node metastases disappeared completely.
16 patients enrolled in the clinical trial (as of the time of the trial)
The company underwent PMDA review and a conformity assessment and received a notice of the results. Deliberation by the Pharmaceutical Affairs and Food Sanitation Council under the Ministry of Health, Labour and Welfare is expected. Manish Shah (マニッシュ・シャー) is the principal investigator for this trial. Further details of capital and personnel relationships are Not disclosed.
PMDA is an incorporated administrative agency responsible for reviewing pharmaceuticals and other products. The Ministry of Health, Labour and Welfare is the government ministry overseeing the Pharmaceutical Affairs and Food Sanitation Council. Manish Shah (マニッシュ・シャー) is the principal investigator for this trial and is affiliated with Cornell University. Further details are Not disclosed.
The company has indicated plans to begin sales of OBP-301, but the specific amount or percentage of its impact on financial results is Not disclosed.
The company does not address Contract Value / Offering price.
Clinical trial results reported at IOVC2026 (International Oncolytic Virus Conference)
| Item | Details |
|---|---|
| Names of Products / Services Covered | OBP-301, Pembrolizumab |
| Counterparty | Pharmaceuticals and Medical Devices Agency (PMDA), Ministry of Health, Labour and Welfare, Cornell University, Manish Shah (マニッシュ・シャー) |
| Counterparty overview | PMDA is an incorporated administrative agency responsible for reviewing pharmaceuticals and other products. The Ministry of Health, Labour and Welfare is the government ministry overseeing the Pharmaceutical Affairs and Food Sanitation Council. Manish Shah (マニッシュ・シャー) is the principal investigator for this trial and is affiliated with Cornell University. Further details are Not disclosed. |
| Relationship with the Company | The company underwent PMDA review and a conformity assessment and received a notice of the results. Deliberation by the Pharmaceutical Affairs and Food Sanitation Council under the Ministry of Health, Labour and Welfare is expected. Manish Shah (マニッシュ・シャー) is the principal investigator for this trial. Further details of capital and personnel relationships are Not disclosed. |
| Launch date | Fiscal year ending December 2026 (planned) |
| Applicable area | Third-line treatment for adenocarcinoma of the stomach and esophagus |
| Quantitative Effects | Clear tumor shrinkage was observed in 3 of 16 patients, 2 of whom survived for more than 5 years. In 1 patient, the primary gastric and esophageal tumors and lymph node metastases disappeared completely. |
| Usage history | 16 patients enrolled in the clinical trial (as of the time of the trial) |
| Impact on Business Performance | The company has indicated plans to begin sales of OBP-301, but the specific amount or percentage of its impact on financial results is Not disclosed. |
| Source | Clinical trial results reported at IOVC2026 (International Oncolytic Virus Conference) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Selected questions received from shareholders, investors and other stakeholders were answered to ensure fair disclosure of information.